Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.
| Revenue (TTM) | $25.84B |
| Gross Profit (TTM) | $16.95B |
| EBITDA | $7.38B |
| Operating Margin | 27.00% |
| Return on Equity | 16.50% |
| Return on Assets | 8.16% |
| Revenue/Share (TTM) | $67.50 |
| Book Value | $62.54 |
| Price-to-Book | 4.92 |
| Price-to-Sales (TTM) | 4.50 |
| EV/Revenue | 5.02 |
| EV/EBITDA | 18.60 |
| Quarterly Earnings Growth (YoY) | 44.10% |
| Quarterly Revenue Growth (YoY) | 9.40% |
| Shares Outstanding | $383.57M |
| Float | $348.14M |
| % Insiders | 5.36% |
| % Institutions | 82.89% |
Volatility is currently contracting
Both Intuitive Surgical and Stryker just posted their fifth straight earnings beat, and Wall Street is cheering for both. But a structural difference buried inside their business models quietly separates a compounder from a cyclical recovery story.
SYK's FDA-cleared SportSuite Vision brings Apple Vision Pro into hip arthroscopy, strengthening its digital surgery push and Sports Medicine portfolio.
SYK's planned ZuriMED acquisition adds the FiberLocker System, aiming to strengthen its shoulder portfolio and rotator cuff care capabilities.
SportSuite Vision brings spatial computing into the operating room, providing surgeons access to critical clinical information Stryker announced the successful completion of the first surgical procedure, a hip arthroscopy, using SportSuite Vision on Apple Vision Pro at a leading academic medical center. Stryker received FDA De Novo authorization for the first surgical application for intraoperative use with Apple Vision Pro, SportSuite Vision.
Portage, Mich., USA, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK), a global leader in medical technologies, announced it has signed a definitive agreement to acquire ZuriMED, a privately held company and developer of the FiberLocker® System. This commercialized technology provides a novel approach for rotator cuff augmentation with increased biomechanical strength to address a key clinical failure mode in rotator cuff repair.
Investors interested in Medical - Products stocks are likely familiar with Prestige Consumer Healthcare (PBH) and Stryker (SYK). But which of these two stocks offers value investors a better bang for their buck right now?
Portage, Michigan, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in the 2026 Wells Fargo Healthcare Conference on Tuesday, September 8, 2026, at the Encore Boston Harbor.
Investors need to pay close attention to SYK stock based on the movements in the options market lately.
SYK's resilient demand, Mako robotics growth and margin gains support its outlook despite cyber and supply disruptions.
Stryker (SYK) rebounded in Q2 with 9% organic growth, restoring confidence after a weak Q1. Both MedSurg & Neurotech and Orthopaedics segments sharply accelerated, indicating Q1 weakness was temporary. Guidance was modestly adjusted, but demand remains strong and growth is broad-based across product lines.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on SYK and any ticker you trade — then tracks every position and per-strategy win rate.
